Sanjeev Sethi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4567592/publications.pdf

Version: 2024-02-01

232 papers	17,890 citations	9234 74 h-index	16127 124 g-index
236 all docs	236 docs citations	236 times ranked	9498 citing authors

#	Article	IF	Citations
1	KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney International, 2021, 100, S1-S276.	2.6	782
2	Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney International, 2018, 93, 789-796.	2.6	532
3	C3 glomerulopathy: consensus report. Kidney International, 2013, 84, 1079-1089.	2.6	505
4	Membranoproliferative Glomerulonephritis â€" A New Look at an Old Entity. New England Journal of Medicine, 2012, 366, 1119-1131.	13.9	442
5	Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease): An Update. Journal of the American Society of Nephrology: JASN, 2005, 16, 1392-1403.	3.0	354
6	Diagnosis of monoclonal gammopathy of renal significance. Kidney International, 2015, 87, 698-711.	2.6	339
7	The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nature Reviews Nephrology, 2019, 15, 45-59.	4.1	330
8	Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney International, 2021, 100, 753-779.	2.6	325
9	Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. New England Journal of Medicine, 2019, 381, 36-46.	13.9	324
10	Diagnosis of IgG4-Related Tubulointerstitial Nephritis. Journal of the American Society of Nephrology: JASN, 2011, 22, 1343-1352.	3.0	322
11	A Proposal for a Serology-Based Approach to Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2017, 28, 421-430.	3.0	273
12	C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney International, 2012, 82, 465-473.	2.6	264
13	Renal Monoclonal Immunoglobulin Deposition Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 231-239.	2.2	240
14	Biopsy-Proven Acute Interstitial Nephritis, 1993-2011: AÂCaseÂSeries. American Journal of Kidney Diseases, 2014, 64, 558-566.	2.1	235
15	New Approaches to the Treatment of Dense Deposit Disease. Journal of the American Society of Nephrology: JASN, 2007, 18, 2447-2456.	3.0	231
16	C3 glomerulopathy â€" understanding a rare complement-driven renal disease. Nature Reviews Nephrology, 2019, 15, 129-143.	4.1	223
17	Neural epidermal growth factor-like 1 proteinÂ(NELL-1) associated membranous nephropathy. Kidney International, 2020, 97, 163-174.	2.6	213
18	Renal Amyloidosis. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1515-1523.	2.2	212

#	Article	IF	Citations
19	Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN. Journal of the American Society of Nephrology: JASN, 2016, 27, 1278-1287.	3.0	210
20	Exostosin 1/Exostosin 2â€“Associated Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2019, 30, 1123-1136.	3.0	198
21	FcÎ³RIII Mediates Neutrophil Recruitment to Immune Complexes. Immunity, 2001, 14, 693-704.	6.6	193
22	Differentiating Primary, Genetic, and Secondary FSGS in Adults: A Clinicopathologic Approach. Journal of the American Society of Nephrology: JASN, 2018, 29, 759-774.	3.0	186
23	Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway. Kidney International, 2009, 75, 952-960.	2.6	178
24	Fibrillary Glomerulonephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 775-784.	2.2	177
25	Membranoproliferative Glomerulonephritis: Pathogenetic Heterogeneity and Proposal for a New Classification. Seminars in Nephrology, 2011, 31, 341-348.	0.6	175
26	Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. Kidney International, 2012, 81, 434-441.	2.6	175
27	Clinicopathologic Correlations in Multiple Myeloma: A Case Series of 190 Patients With Kidney Biopsies. American Journal of Kidney Diseases, 2012, 59, 786-794.	2.1	174
28	A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction. Journal of the American Society of Nephrology: JASN, 2017, 28, 1306-1313.	3.0	174
29	Oxidized Omega-3 Fatty Acids Inhibit NF-ÎºB Activation Via a PPARÎ±-Dependent Pathway. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 1621-1627.	1.1	171
30	Transplant Glomerulopathy: Risk and Prognosis Related to Anti-Human Leukocyte Antigen Class II Antibody Levels. Transplantation, 2008, 86, 681-685.	0.5	168
31	Membranous nephropathy. Nature Reviews Disease Primers, 2021, 7, 69.	18.1	167
32	Causes of Alternative Pathway Dysregulation in Dense Deposit Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 265-274.	2.2	166
33	Laser microdissection and mass spectrometryâ€“based proteomics aids the diagnosis and typing of renal amyloidosis. Kidney International, 2012, 82, 226-234.	2.6	166
34	Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement. Kidney International, 2013, 83, 293-299.	2.6	161
35	A proposal for standardized grading of chronic changes in native kidney biopsy specimens. Kidney International, 2017, 91, 787-789.	2.6	161
36	Discovery of a Spontaneous Genetic Mouse Model of Preeclampsia. Hypertension, 2002, 39, 337-342.	1.3	160

#	Article	IF	Citations
37	Postinfectious Glomerulonephritis in the Elderly. Journal of the American Society of Nephrology: JASN, 2011, 22, 187-195.	3.0	159
38	Membranoproliferative Glomerulonephritis Secondary to Monoclonal Gammopathy. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 770-782.	2.2	156
39	Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPARÎ±. Blood, 2002, 100, 1340-1346.	0.6	150
40	C3 Glomerulonephritis Associated With Monoclonal Gammopathy: A Case Series. American Journal of Kidney Diseases, 2013, 62, 506-514.	2.1	150
41	Semaphorin 3Bâ€“associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients. Kidney International, 2020, 98, 1253-1264.	2.6	138
42	New â€˜Antigensâ€™ in Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2021, 32, 268-278.	3.0	138
43	Membranous glomerulonephritis is a manifestation of IgG4-related disease. Kidney International, 2013, 83, 455-462.	2.6	136
44	Proliferative Glomerulonephritis Secondary to Dysfunction of the Alternative Pathway of Complement. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1009-1017.	2.2	133
45	How I treat amyloidosis: the importance of accurate diagnosis and amyloid typing. Blood, 2012, 120, 3206-3213.	0.6	132
46	Recurrent membranoproliferative glomerulonephritis after kidney transplantation. Kidney International, 2010, 77, 721-728.	2.6	128
47	Idiopathic Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 905-919.	2.2	126
48	Clinical Findings, Pathology, and Outcomes of C3GN after Kidney Transplantation. Journal of the American Society of Nephrology: JASN, 2014, 25, 1110-1117.	3.0	126
49	Hemolysis and Acute Kidney Failure. American Journal of Kidney Diseases, 2010, 56, 780-784.	2.1	124
50	Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptorÂantibodies. Kidney International, 2019, 95, 429-438.	2.6	123
51	The Complexity and Heterogeneity of Monoclonal Immunoglobulinâ€“Associated Renal Diseases. Journal of the American Society of Nephrology: JASN, 2018, 29, 1810-1823.	3.0	122
52	Proliferative Glomerulonephritis with Monoclonal IgG Deposits Recurs in the Allograft. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 122-132.	2.2	117
53	Mass Spectrometryâ€“Based Proteomic Diagnosis of Renal Immunoglobulin Heavy Chain Amyloidosis. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 2180-2187.	2.2	109
54	Immunotactoid glomerulopathy: clinicopathologic and proteomic study. Nephrology Dialysis Transplantation, 2012, 27, 4137-4146.	0.4	109

#	Article	IF	Citations
55	DNAJB9 Is a Specific Immunohistochemical Marker for Fibrillary Glomerulonephritis. Kidney International Reports, 2018, 3, 56-64.	0.4	109
56	Dense Deposit Disease Associated With Monoclonal Gammopathy of Undetermined Significance. American Journal of Kidney Diseases, 2010, 56, 977-982.	2.1	107
57	C4d as a Diagnostic Tool in Proliferative GN. Journal of the American Society of Nephrology: JASN, 2015, 26, 2852-2859.	3.0	106
58	Membranoproliferative glomerulonephritis with masked monotypic immunoglobulin deposits. Kidney International, 2015, 88, 867-873.	2.6	103
59	The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. Kidney International, 2013, 83, 463-470.	2.6	101
60	The clinicopathologic characteristics and outcome of atypical anti-glomerular basement membrane nephritis. Kidney International, 2016, 89, 897-908.	2.6	95
61	Myeloproliferative neoplasms cause glomerulopathy. Kidney International, 2011, 80, 753-759.	2.6	93
62	Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephrology Dialysis Transplantation, 2011, 26, 2865-2871.	0.4	92
63	A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P.) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Transplantation, 2014, 29, 1570-1577.	0.4	92
64	Hematologic Characteristics of Proliferative Glomerulonephritides With Nonorganized Monoclonal Immunoglobulin Deposits. Mayo Clinic Proceedings, 2015, 90, 587-596.	1.4	92
65	Protocadherin 7â€“Associated Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2021, 32, 1249-1261.	3.0	92
66	Clinical characteristics, causes and outcomes of acute interstitial nephritis in the elderly. Kidney International, 2015, 87, 458-464.	2.6	91
67	DnaJ Heat Shock Protein Family B Member 9 Is a Novel Biomarker for Fibrillary GN. Journal of the American Society of Nephrology: JASN, 2018, 29, 51-56.	3.0	90
68	Mycophenolate Mofetil for Induction and Maintenance of Remission in Microscopic Polyangiitis with Mild to Moderate Renal Involvementâ€”A Prospective, Open-Label Pilot Trial. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 445-453.	2.2	89
69	Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway. Journal of the American Society of Nephrology: JASN, 2015, 26, 2917-2929.	3.0	84
70	Characterization and outcomes of renal leukocyte chemotactic factor 2-associated amyloidosis. Kidney International, 2014, 86, 370-377.	2.6	82
71	C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic. Mayo Clinic Proceedings, 2018, 93, 991-1008.	1.4	82
72	Focal segmental glomerulosclerosis: towards a better understanding for the practicing nephrologist. Nephrology Dialysis Transplantation, 2015, 30, 375-384.	0.4	81

#	Article	IF	Citations
73	Soluble CR1 Therapy Improves Complement Regulation in C3 Glomerulopathy. Journal of the American Society of Nephrology: JASN, 2013, 24, 1820-1829.	3.0	80
74	Digital Pathology Evaluation in the Multicenter Nephrotic Syndrome Study Network (NEPTUNE). Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1449-1459.	2.2	80
75	Laser Microdissection and Proteomic Analysis of Amyloidosis, Cryoglobulinemic GN, Fibrillary GN, and Immunotactoid Glomerulopathy. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 915-921.	2.2	80
76	Monoclonal Gammopathyâ€“Associated Proliferative Glomerulonephritis. Mayo Clinic Proceedings, 2013, 88, 1284-1293.	1.4	78
77	Thrombotic microangiopathy associated with monoclonal gammopathy. Kidney International, 2017, 91, 691-698.	2.6	78
78	Standardized classification and reporting of glomerulonephritis. Nephrology Dialysis Transplantation, 2019, 34, 193-199.	0.4	78
79	C3 glomerulopathy associated with monoclonal IgÂis a distinct subtype. Kidney International, 2018, 94, 178-186.	2.6	77
80	Diagnosis of complement alternative pathway disorders. Kidney International, 2016, 89, 278-288.	2.6	74
81	Urinary Albumin Excretion Patterns of Patients with Cast Nephropathy and Other Monoclonal Gammopathyâ€“Related Kidney Diseases. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1964-1968.	2.2	72
82	Crystalline nephropathy due to 2,8-dihydroxyadeninuria: an under-recognized cause of irreversible renal failure. Nephrology Dialysis Transplantation, 2010, 25, 1909-1915.	0.4	67
83	Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney. Nephrology Dialysis Transplantation, 2012, 27, 1097-1101.	0.4	61
84	Pathology of Renal Diseases Associated with Dysfunction of the Alternative Pathway of Complement: C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome (aHUS). Seminars in Thrombosis and Hemostasis, 2014, 40, 416-421.	1.5	61
85	Focal and segmental glomerulosclerosis: clinical and kidney biopsy correlations. CKJ: Clinical Kidney Journal, 2014, 7, 531-537.	1.4	60
86	Mass spectrometry based proteomics in the diagnosis of kidney disease. Current Opinion in Nephrology and Hypertension, 2013, 22, 273-280.	1.0	59
87	Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: results of a proteomic analysis. Nephrology Dialysis Transplantation, 2017, 32, i139-i145.	0.4	59
88	Spectrum of manifestations of monoclonal gammopathy-associated renal lesions. Current Opinion in Nephrology and Hypertension, 2016, 25, 127-137.	1.0	57
89	Novel Type of Renal Amyloidosis Derived from Apolipoprotein-CII. Journal of the American Society of Nephrology: JASN, 2017, 28, 439-445.	3.0	57
90	Complement in Secondary Thrombotic Microangiopathy. Kidney International Reports, 2021, 6, 11-23.	0.4	56

#	Article	IF	Citations
91	In Patients with Membranous Lupus Nephritis, Exostosin-Positivity and Exostosin-Negativity Represent Two Different Phenotypes. Journal of the American Society of Nephrology: JASN, 2021, 32, 695-706.	3.0	56
92	Thrombotic Microangiopathy Care Pathway: A Consensus Statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group. Mayo Clinic Proceedings, 2016, 91, 1189-1211.	1.4	55
93	Clinical and pathological phenotype of genetic causes of focal segmental glomerulosclerosis in adults. CKJ: Clinical Kidney Journal, 2018, 11, 179-190.	1.4	55
94	Congophilic Fibrillary Glomerulonephritis: A Case Series. American Journal of Kidney Diseases, 2018, 72, 325-336.	2.1	55
95	Kidney Biopsy Findings in Patients With COVID-19, Kidney Injury, and Proteinuria. American Journal of Kidney Diseases, 2021, 77, 465-468.	2.1	54
96	Therapeutic trials in adult FSGS: lessons learned and the road forward. Nature Reviews Nephrology, 2021, 17, 619-630.	4.1	53
97	Successful Pregnancy and Delivery of a Healthy Newborn Despite Transplacental Transfer of Antimyeloperoxidase Antibodies From a Mother With Microscopic Polyangiitis. American Journal of Kidney Diseases, 2009, 54, 542-545.	2.1	52
98	Idiopathic membranoproliferative glomerulonephritis: does it exist?. Nephrology Dialysis Transplantation, 2012, 27, 4288-4294.	0.4	51
99	Medullary amyloidosis associated with apolipoprotein A-IV deposition. Kidney International, 2012, 81, 201-206.	2.6	51
100	Proteomic Analysis of Complement Proteins in Membranous Nephropathy. Kidney International Reports, 2020, 5, 618-626.	0.4	51
101	Inhibition of phagocyte-endothelium interactions by oxidized fatty acids: A natural anti-inflammatory mechanism?. Translational Research, 1996, 128, 27-38.	2.4	49
102	Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft. Kidney International, 2018, 94, 159-169.	2.6	49
103	Crystal-storing histiocytosis involving the kidney in a low-grade B-cell lymphoproliferative disorder. American Journal of Kidney Diseases, 2002, 39, 183-188.	2.1	48
104	Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis with Severe Kidney Disease. Journal of the American Society of Nephrology: JASN, 2020, 31, 2688-2704.	3.0	48
105	The Rat Femoral Arteriovenous Fistula Model: Increased Expression of Matrix Metalloproteinaseâ€“2 and â˜9 at the Venous Stenosis. Journal of Vascular and Interventional Radiology, 2008, 19, 587-594.	0.2	47
106	Renal Amyloidosis Associated With a Novel Sequence Variant of Gelsolin. American Journal of Kidney Diseases, 2013, 61, 161-166.	2.1	47
107	Hematopoietic Stem Cell Transplant-Membranous Nephropathy Is Associated with Protocadherin FAT1. Journal of the American Society of Nephrology: JASN, 2022, 33, 1033-1044.	3.0	47
108	Neutrophils: game changers in glomerulonephritis?. Trends in Molecular Medicine, 2010, 16, 368-378.	3.5	46

#	Article	IF	Citations
109	Incidence, prevalence, mortality and chronic renal damage of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a 20-year population-based cohort. Nephrology Dialysis Transplantation, 2019, 34, 1508-1517.	0.4	46
110	C4 Nephritic Factors in C3 Glomerulopathy: A Case Series. American Journal of Kidney Diseases, 2017, 70, 834-843.	2.1	45
111	A Target Antigenâ€"Based Approach to the Classification of Membranous Nephropathy. Mayo Clinic Proceedings, 2021, 96, 577-591.	1.4	45
112	Renal failure due to combined cast nephropathy, amyloidosis and light-chain deposition disease. Nephrology Dialysis Transplantation, 2010, 25, 1340-1343.	0.4	43
113	IgG4-Related Tubulointerstitial Nephritis With Membranous Nephropathy. American Journal of Kidney Diseases, 2011, 58, 320-324.	2.1	42
114	Clinical, biopsy, and mass spectrometry characteristics of renal apolipoprotein A-IVÂamyloidosis. Kidney International, 2016, 90, 658-664.	2.6	42
115	Consensus definitions for glomerular lesions by light and electron microscopy: recommendations from a working group of the Renal Pathology Society. Kidney International, 2020, 98, 1120-1134.	2.6	41
116	Acute Kidney Injury in Severe COVID-19 Has Similarities to Sepsis-Associated Kidney Injury. Mayo Clinic Proceedings, 2021, 96, 2561-2575.	1.4	41
117	The Incidence of Primary vs Secondary Focal Segmental Glomerulosclerosis: A Clinicopathologic Study. Mayo Clinic Proceedings, 2017, 92, 1772-1781.	1.4	39
118	Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both. Leukemia and Lymphoma, 2015, 56, 3357-3364.	0.6	36
119	IgD Heavy-Chain Deposition Disease. Journal of the American Society of Nephrology: JASN, 2015, 26, 784-790.	3.0	35
120	Renal extramedullary hematopoiesis: interstitial and glomerular pathology. Modern Pathology, 2015, 28, 1574-1583.	2.9	33
121	Rate and Predictors of Finding Monoclonal Gammopathy of Renal Significance (MGRS) Lesions on Kidney Biopsy in Patients with Monoclonal Gammopathy. Journal of the American Society of Nephrology: JASN, 2020, 31, 2400-2411.	3.0	33
122	Safety and Efficacy of Daratumumab in Patients with Proliferative GN with Monoclonal Immunoglobulin Deposits. Journal of the American Society of Nephrology: JASN, 2021, 32, 1163-1173.	3.0	33
123	Membranous Nephropathy With Crescents: A Series of 19 Cases. American Journal of Kidney Diseases, 2014, 64, 66-73.	2.1	32
124	Immunotactoid glomerulopathy is a rare entity with monoclonal and polyclonal variants. Kidney International, 2021, 99, 410-420.	2.6	32
125	Inhibition of leukocyteâ€"endothelial interactions by oxidized omega-3 fatty acids: a novel mechanism for the anti-inflammatory effects of omega-3 fatty acids in fish oil. Redox Report, 2002, 7, 369-378.	1.4	31
126	Secondary Focal and Segmental Glomerulosclerosis Associated With Single-Nucleotide Polymorphisms in the Genes Encoding Complement Factor H and C3. American Journal of Kidney Diseases, 2012, 60, 316-321.	2.1	31

#	Article	IF	Citations
127	Association of a Novel Complement Factor H Mutation With Severe Crescentic and Necrotizing Glomerulonephritis. American Journal of Kidney Diseases, 2012, 60, 126-132.	2.1	31
128	The sensitivity and specificity of the routine kidney biopsy immunofluorescence panel are inferior to diagnosing renal immunoglobulin-derived amyloidosis by mass spectrometry. Kidney International, 2019, 96, 1005-1009.	2.6	30
129	Membranoproliferative glomerulonephritis associated with autoimmune diseases. Journal of Nephrology, 2014, 27, 165-171.	0.9	29
130	Characterization of C3 in C3 glomerulopathy. Nephrology Dialysis Transplantation, 2017, 32, gfw290.	0.4	29
131	Pathology and diagnosis of renal non-AL amyloidosis. Journal of Nephrology, 2018, 31, 343-350.	0.9	29
132	Noninvasive Diagnosis of PLA2R-Associated Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1833-1839.	2.2	27
133	Bortezomib-induced acute interstitial nephritis. Nephrology Dialysis Transplantation, 2015, 30, 1225-1229.	0.4	25
134	Kidney biopsy chronicity grading in antineutrophil cytoplasmic antibody-associated vasculitis. Nephrology Dialysis Transplantation, 2022, 37, 1710-1721.	0.4	25
135	Membranoproliferative Glomerulonephritis: The Role for Laser Microdissection and Mass Spectrometry. American Journal of Kidney Diseases, 2014, 63, 324-328.	2.1	24
136	Refractory atypical hemolytic uremic syndrome with monoclonal gammopathy responsive to bortezomib-based therapy. Clinical Nephrology, 2015, 83 (2015), 363-369.	0.4	24
137	DNAJB9-positive monotypic fibrillary glomerulonephritis is not associated with monoclonal gammopathy in the vast majority of patients. Kidney International, 2020, 98, 498-504.	2.6	24
138	Acute glomerulonephritis. Lancet, The, 2022, 399, 1646-1663.	6.3	24
139	C4 Dense-Deposit Disease. New England Journal of Medicine, 2014, 370, 784-786.	13.9	23
140	C4 Glomerulopathy: A Disease Entity Associated WithÂC4dÂDeposition. American Journal of Kidney Diseases, 2016, 67, 949-953.	2.1	23
141	SHEDDING LIGHT ON FUNDUS DRUSEN ASSOCIATED WITH MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS. Retinal Cases and Brief Reports, 2016, 10, 72-78.	0.3	22
142	Clinical, biopsy, and mass spectrometry findings of renal gelsolin amyloidosis. Kidney International, 2017, 91, 964-971.	2.6	21
143	Apolipoprotein CII Amyloidosis Associated With p.Lys41Thr Mutation. Kidney International Reports, 2018, 3, 1193-1201.	0.4	21
144	Etiology-Based Diagnostic Approach to Proliferative Glomerulonephritis. American Journal of Kidney Diseases, 2014, 63, 561-566.	2.1	20

#	Article	IF	Citations
145	Identification of Genetic Causes of Focal Segmental Glomerulosclerosis Increases With Proper Patient Selection. Mayo Clinic Proceedings, 2021, 96, 2342-2353.	1.4	20
146	Coexistence of Myeloma Cast Nephropathy, Light Chain Deposition Disease, and Nonamyloid Fibrils in a Patient With Multiple Myeloma. American Journal of Kidney Diseases, 2010, 56, 971-976.	2.1	19
147	Leukocyte chemotactic factor 2 amyloidosis cannot be reliably diagnosed by immunohistochemical staining. Human Pathology, 2014, 45, 1445-1450.	1.1	19
148	Manifestations of Complement-Mediated and Immune Complex-Mediated Membranoproliferative Glomerulonephritis. Ophthalmology, 2016, 123, 1588-1594.	2.5	19
149	Membranous nephropathy: a single diseaseÂor a pattern of injury resulting from different diseases. CKJ: Clinical Kidney Journal, 2021, 14, 2166-2169.	1.4	19
150	Immune-Complex Glomerulonephritis After COVID-19 Infection. Kidney International Reports, 2021, 6, 1170-1173.	0.4	19
151	ANCA-positive crescentic glomerulonephritis associated with minocycline therapy. American Journal of Kidney Diseases, 2003, 42, e9.1-e9.5.	2.1	18
152	C3 glomerulonephritis and autoimmune disease: more than a fortuitous association?. Journal of Nephrology, 2016, 29, 203-209.	0.9	18
153	The association of microhematuria with mesangial hypercellularity, endocapillary hypercellularity, crescent score and renal outcomes in immunoglobulin A nephropathy. Nephrology Dialysis Transplantation, 2021, 36, 840-847.	0.4	18
154	Diagnostic Utility of Complement Serology for Atypical Hemolytic Uremic Syndrome. Mayo Clinic Proceedings, 2018, 93, 1351-1362.	1.4	17
155	An Open-Label Pilot Study ofÂAdrenocorticotrophic Hormone inÂtheÂTreatment of IgA Nephropathy atÂHigh Risk of Progression. Kidney International Reports, 2020, 5, 58-65.	0.4	17
156	Triamterene Crystalline Nephropathy. American Journal of Kidney Diseases, 2014, 63, 148-152.	2.1	16
157	Disappearance of immunoglobulins from persistent renal amyloid deposits following stem cell transplantation for heavy-and light-chain amyloidosis. Nephrology Dialysis Transplantation, 2015, 30, 1151-1155.	0.4	16
158	Renal involvement in Neimann-Pick Disease. CKJ: Clinical Kidney Journal, 2009, 2, 448-451.	1.4	15
159	AA amyloidosis associated with hepatitis B. Nephrology Dialysis Transplantation, 2011, 26, 2407-2412.	0.4	15
160	What are we missing in the clinical trials of focal segmental glomerulosclerosis?. Nephrology Dialysis Transplantation, 2017, 32, i14-i21.	0.4	15
161	C3 glomerulonephritis with a severe crescentic phenotype. Pediatric Nephrology, 2017, 32, 1625-1633.	0.9	15
162	Granulomatous interstitial nephritis secondary to chronic lymphocytic leukemia/small lymphocytic lymphoma. Annals of Diagnostic Pathology, 2015, 19, 130-136.	0.6	14

#	Article	IF	Citations
163	Recurrent Light Chain Proximal Tubulopathy in a KidneyÂAllograft. American Journal of Kidney Diseases, 2016, 68, 483-487.	2.1	14
164	Treatment of primary membranous nephropathy: where are we now?. Journal of Nephrology, 2018, 31, 489-502.	0.9	14
165	Thrombotic microangiopathy in children. Pediatric Nephrology, 2022, 37, 1967-1980.	0.9	14
166	AA Amyloidosis Associated With Systemic-Onset Juvenile Idiopathic Arthritis. American Journal of Kidney Diseases, 2013, 62, 834-838.	2.1	13
167	Proliferative C4 Dense Deposit Disease, Acute ThromboticÂMicroangiopathy, a Monoclonal Gammopathy, andÂAcute Kidney Failure. American Journal of Kidney Diseases, 2016, 67, 479-482.	2.1	13
168	Recurrence of DNAJB9-Positive Fibrillary Glomerulonephritis After Kidney Transplantation: A Case Series. American Journal of Kidney Diseases, 2020, 76, 500-510.	2.1	13
169	Association of Histologic Parameters with Outcome in C3 Glomerulopathy and Idiopathic Immunoglobulin-Associated Membranoproliferative Glomerulonephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 994-1007.	2.2	13
170	Acute Renal Failure in a Renal Allograft: An Unusual Infectious Cause of Thrombotic Microangiopathy. American Journal of Kidney Diseases, 2005, 46, 159-162.	2.1	12
171	Linear anti-glomerular basement membrane IgG but no glomerular disease: Goodpasture's syndrome restricted to the lung. Nephrology Dialysis Transplantation, 2007, 22, 1233-1235.	0.4	12
172	Unusual Casts in a Case of Multiple Myeloma. American Journal of Kidney Diseases, 2009, 54, 970-974.	2.1	12
173	Recurrent AA Amyloidosis in a Kidney Transplant. American Journal of Kidney Diseases, 2011, 57, 941-944.	2.1	12
174	Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease. Pediatric Nephrology, 2016, 31, 683-687.	0.9	12
175	Histiocytic and Nonhistiocytic Glomerular Lesions: Foam Cells and Their Mimickers. American Journal of Kidney Diseases, 2016, 67, 329-336.	2.1	12
176	Cryofibrinogen-Associated Glomerulonephritis. American Journal of Kidney Diseases, 2017, 69, 302-308.	2.1	12
177	Marfan Syndrome, MPGN, and Bacterial Endocarditis. American Journal of Kidney Diseases, 2008, 51, 697-701.	2.1	11
178	Recurrence of Amyloidosis in a Kidney Transplant. American Journal of Kidney Diseases, 2010, 56, 394-398.	2.1	11
179	Histiocytic glomerulopathy associated with macrophage activation syndrome. CKJ: Clinical Kidney Journal, 2015, 8, 157-160.	1.4	11
180	A Case of Fibrillary Glomerulonephritis With Linear Immunoglobulin G Staining of the Glomerular Capillary Walls. Archives of Pathology and Laboratory Medicine, 2001, 125, 534-536.	1.2	11

#	Article	IF	Citations
181	Renal Thrombotic Microangiopathy in a Genetic Model of Hypertension in Mice. Experimental Biology and Medicine, 2006, 231, 196-203.	1.1	10
182	Epstein-Barr virus-associated nephrotic syndrome. CKJ: Clinical Kidney Journal, 2012, 5, 50-52.	1.4	10
183	C3 Glomerulonephritis Associated With Complement Factor B Mutation. American Journal of Kidney Diseases, 2015, 65, 520-521.	2.1	10
184	New-Onset Proteinuria With Massive Amorphous Glomerular Deposits. American Journal of Kidney Diseases, 2010, 55, 749-754.	2.1	9
185	Renal hemodynamic effects of the HMG-CoA reductase inhibitors in autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2016, 31, 1290-1295.	0.4	9
186	Rapidly progressive glomerulonephritis due to coexistent anti-glomerular basement membrane disease and fibrillary glomerulonephritis. CKJ: Clinical Kidney Journal, 2016, 9, 97-101.	1.4	9
187	Membranous Nephropathy With Extensive Tubular Basement Membrane Deposits Following Allogeneic Hematopoietic Cell Transplant: A Report of 5 Cases. American Journal of Kidney Diseases, 2022, 79, 904-908.	2.1	9
188	Global Glomerulosclerosis in Kidney Biopsies With Differing Amounts of Cortex: A Clinical-Pathologic Correlation Study. Kidney Medicine, 2019, 1, 153-161.	1.0	8
189	Granulomatous Interstitial Nephritis Associated With Disseminated Histoplasmosis in an Immunocompetent Patient. American Journal of Kidney Diseases, 2011, 58, 1018-1021.	2.1	7
190	Frequent-relapsing, steroid-dependent minimal change disease: is rituximab the answer?. Nephrology Dialysis Transplantation, 2014, 29, 722-727.	0.4	7
191	Overlap of ultrastructural findings in C3 glomerulonephritis and dense deposit disease. Kidney International, 2015, 88, 1449-1450.	2.6	7
192	C4d as a marker for masked immune deposits. Kidney International, 2016, 90, 223-224.	2.6	7
193	Karyomegalic interstitial nephritis in a renal allograft. American Journal of Transplantation, 2019, 19, 285-290.	2.6	7
194	Standardized reporting of monoclonal immunoglobulinâ€“associated renal diseases: recommendations from a Mayo Clinic/Renal Pathology Society Working Group. Kidney International, 2020, 98, 310-313.	2.6	7
195	Circulating Complement Levels and C3 Glomerulopathy. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1829-1831.	2.2	6
196	Treatment of ANCA-Associated Vasculitis: New Therapies and a Look at Old Entities. Advances in Chronic Kidney Disease, 2014, 21, 182-193.	0.6	6
197	Leishmaniasis-Associated Membranoproliferative Glomerulonephritis With Massive Complement Deposition. Kidney International Reports, 2016, 1, 125-130.	0.4	6
198	Renal and Pulmonary Dense DepositÂDisease Presenting as Pulmonary-Renal Syndrome. Kidney International Reports, 2018, 3, 755-761.	0.4	6

#	Article	IF	Citations
199	The characteristics of patients with kidney light chain deposition disease concurrent with light chain amyloidosis. Kidney International, 2022, 101, 152-163.	2.6	6
200	The characteristics of seronegative and seropositive non-hepatitis-associated cryoglobulinemic glomerulonephritis. Kidney International, 2022, 102, 382-394.	2.6	6
201	Kidney Histopathology in ANCA-Associated Vasculitides Treated with Plasma Exchange. Journal of the American Society of Nephrology: JASN, 2022, 33, 1223-1224.	3.0	5
202	BK nephropathy with glomerular involvement. Kidney International, 2018, 94, 432.	2.6	4
203	The Changing Spectrum of Heroin-Associated Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 975-976.	2.2	4
204	Intravascular cardiac lipoproteinosis: extrarenal manifestation of lipoprotein glomerulopathy. Cardiovascular Pathology, 2019, 42, 6-9.	0.7	3
205	Open-Label Clinical Trials of Oral Pulse Dexamethasone for Adults with Idiopathic Nephrotic Syndrome. American Journal of Nephrology, 2019, 49, 377-385.	1.4	3
206	Novel Genetic Variants in Complement-Mediated Thrombotic Microangiopath. Blood, 2015, 126, 1050-1050.	0.6	3
207	High-dose melphalan and autologous hematopoietic stem cell transplant in patientÂwith C3 glomerulonephritis associatedÂwith monoclonal gammopathy. Clinical Nephrology, 2018, 89, 291-299.	0.4	3
208	Impact of Consensus Definitions on Identification of Glomerular Lesions by Light and Electron Microscopy. Kidney International Reports, 2022, 7, 78-86.	0.4	3
209	Advances in basic science and translational medicine. Nature Reviews Nephrology, 2015, 11, 67-68.	4.1	2
210	A rare case of crystalglobulinemia. Journal of Onco-Nephrology, 2019, 3, 53-57.	0.3	2
211	Renal biopsy findings in patients with extreme obesity: more heterogeneous than youÂthink. Kidney International, 2019, 95, 495-498.	2.6	2
212	De novo pauci-immune glomerulonephritis in renal allografts. Modern Pathology, 2020, 33, 440-447.	2.9	2
213	Kidney Injury in Multiple Myeloma: A Kidney Biopsy Teaching Case. Kidney Medicine, 2021, 3, 303-306.	1.0	2
214	Crescentic glomerulonephritis and dense deposit disease in a woman with breast carcinoma on immunosuppressive chemotherapy. American Journal of Kidney Diseases, 2004, 44, e33-7.	2.1	2
215	Membranoproliferative Glomerulonephritis. , 2014, , 77-85.		1
216	Leukocyte chemotactic factor 2 amyloidosis cannot be reliably diagnosed by immunohistochemical stainingâ€"reply. Human Pathology, 2014, 45, 2179-2180.	1.1	1

#	Article	IF	Citations
217	Thrombotic microangiopathy and their mimickers. Nephrology Dialysis Transplantation, 2020, , .	0.4	1
218	Renal Heavy Chain and Heavy+Light Chain Amyloidosis: A Report of 17 Cases and Comparison with Renal Light Chain Amyloidosis. Blood, 2012, 120, 3992-3992.	0.6	1
219	Microsporidium Infectionâ€“Associated Acute Kidney Injury in a Patient With HIV. Kidney Medicine, 2021, 4, 100390.	1.0	1
220	Posaconazole-induced podocyte phospholipidosis. Kidney International, 2022, 101, 654.	2.6	1
221	Proteinuria in a Patient With Discoid Lupus. American Journal of Kidney Diseases, 2009, 54, 567-571.	2.1	0
222	The Author Replys. Kidney International, 2013, 83, 332.	2.6	0
223	In Reply to â€˜C4 Deposition in Glomerular Diseaseâ€™. American Journal of Kidney Diseases, 2016, 68, 817.	2.1	0
224	The Authors Reply. Kidney International, 2017, 92, 517.	2.6	0
225	Authorsâ€™ Reply. Journal of the American Society of Nephrology: JASN, 2018, 29, 2902-2902.	3.0	0
226	The authors reply. Kidney International, 2018, 94, 632-633.	2.6	0
227	Membranoproliferative Glomerulonephritis, Adult. , 2019, , 403-419.		0
228	C3 Glomerulonephritis: A Rare Etiology of the Pulmonary Renal Syndrome. Kidney Medicine, 2019, 1, 36-39.	1.0	0
229	Slowly Unraveling the Mysteries of C3G. American Journal of Kidney Diseases, 2021, 77, 670-672.	2.1	0
230	C3 Glomerulopathies. , 2016, , 633-649.		0
231	Membranoproliferative Glomerulonephritis, Adult. , 2017, , 1-16.		0
232	ATYPICAL HEMOLYTIC UREMIC SYNDROME AND C3 GLOMERULOPATHY: CONCLUSIONS FROM A Â«KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMESÂ» (KDIGO) CONTROVERSIES CONFERENCE. Nephrology (Saint-Petersburg), 2018, 22, 18-39.	0.1	0